Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cancer Biother Radiopharm ; 13(5): 387-93, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10851430

RESUMEN

HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, the rate limiting enzyme in cholesterol synthesis, catalyses mevalonate production and, hence, influence the synthesis of isoprenoid metabolites. It has already been demonstrated that products of the mevalonate pathway play an important role in the progress of the cell cycle and cell survival. Lovastatin (LOV) competitively inhibits HMG-CoA reductase, blocking the synthesis of mevalonic acid and the generation of non-sterol isoprenoids, such as farnesyl residues. The posttranslational farnesylation of p21ras protein is essential for its binding to the membrane and, therefore, for its transforming activity. Considering that p21ras protein was reported to have a significant rol in metastatic behavior of tumor cells, we decided to study LOV as an antimetastatic agent on a rat fibrosarcoma. We demonstrated that a short treatment with LOV diminished primary tumor growth and the number and size of lung experimental metastasis.


Asunto(s)
Antineoplásicos/uso terapéutico , Fibrosarcoma/tratamiento farmacológico , Fibrosarcoma/patología , Lovastatina/uso terapéutico , Animales , División Celular/efectos de los fármacos , Colesterol/sangre , Fibrosarcoma/sangre , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Metástasis de la Neoplasia/patología , Metástasis de la Neoplasia/prevención & control , Ratas , Ratas Endogámicas , Sarcoma Experimental/sangre , Sarcoma Experimental/tratamiento farmacológico , Sarcoma Experimental/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA